Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Recurrent gene mutations detected in canine mast cell tumours by next generation sequencing

M. Vozdova, S. Kubickova, K. Pal, J. Fröhlich, P. Fictum, J. Rubes

. 2020 ; 18 (4) : 509-518. [pub] 20200207

Language English Country Great Britain

Document type Journal Article

Grant support
16-26655S Grantová Agentura České Republiky
LM2015091 Ministerstvo Školství, Mládeže a Tělovýchovy
LQ1601 Ministerstvo Školství, Mládeže a Tělovýchovy
RO 0519 Ministerstvo Zemědělství

Genetic causes of canine mast cell tumours (MCTs), except for mutations in the KIT gene detected in some MCTs, are generally unknown. We used whole exome sequencing to reveal mutation spectra in canine MCTs. We detected somatic mutations in 87 genes including 10 genes recognized as human cancer drivers. Besides KIT, 14 other genes were recurrently mutated. Subsequently, we performed next generation sequencing of a panel of 50 selected genes in additional MCT samples. In this group, the most frequently altered gene was GNB1 showing a recurrent dinucleotide substitution at position of Gly116 in 30% of the MCT samples (n = 6/20) and Ile80 substitution accompanied by a splice region mutation in one case. We extended the study by analysis of the above mentioned GNB1 regions in additional MCT samples by Sanger sequencing, and assessed the overall prevalence of GNB1 mutations to 17.3% (n = 14/81), which is similar to the prevalence of KIT alterations. Our results indicate that GNB1 mutations are probably involved in canine MCT pathogenesis in both cutaneous and subcutaneous MCT cases. As opposed to KIT alterations, the presence of GNB1 mutations did not negatively affect survival times, and our data even showed a trend towards positive prognosis. If our results are confirmed in a larger number of MCTs, an extension of molecular testing of canine MCTs by GNB1 analysis would help to refine the molecular stratification of MCTs, and become useful for targeted treatment strategies.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026404
003      
CZ-PrNML
005      
20211026132930.0
007      
ta
008      
211013s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/vco.12572 $2 doi
035    __
$a (PubMed)31999054
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Vozdova, Miluse $u Department of Genetics and Reproduction, Central European Institute of Technology, Veterinary Research Institute, Brno, Czech Republic
245    10
$a Recurrent gene mutations detected in canine mast cell tumours by next generation sequencing / $c M. Vozdova, S. Kubickova, K. Pal, J. Fröhlich, P. Fictum, J. Rubes
520    9_
$a Genetic causes of canine mast cell tumours (MCTs), except for mutations in the KIT gene detected in some MCTs, are generally unknown. We used whole exome sequencing to reveal mutation spectra in canine MCTs. We detected somatic mutations in 87 genes including 10 genes recognized as human cancer drivers. Besides KIT, 14 other genes were recurrently mutated. Subsequently, we performed next generation sequencing of a panel of 50 selected genes in additional MCT samples. In this group, the most frequently altered gene was GNB1 showing a recurrent dinucleotide substitution at position of Gly116 in 30% of the MCT samples (n = 6/20) and Ile80 substitution accompanied by a splice region mutation in one case. We extended the study by analysis of the above mentioned GNB1 regions in additional MCT samples by Sanger sequencing, and assessed the overall prevalence of GNB1 mutations to 17.3% (n = 14/81), which is similar to the prevalence of KIT alterations. Our results indicate that GNB1 mutations are probably involved in canine MCT pathogenesis in both cutaneous and subcutaneous MCT cases. As opposed to KIT alterations, the presence of GNB1 mutations did not negatively affect survival times, and our data even showed a trend towards positive prognosis. If our results are confirmed in a larger number of MCTs, an extension of molecular testing of canine MCTs by GNB1 analysis would help to refine the molecular stratification of MCTs, and become useful for targeted treatment strategies.
650    _2
$a zvířata $7 D000818
650    _2
$a nemoci psů $x genetika $x patologie $7 D004283
650    _2
$a psi $7 D004285
650    _2
$a proteiny vázající GTP - beta-podjednotky $x genetika $7 D044387
650    _2
$a vysoce účinné nukleotidové sekvenování $x veterinární $7 D059014
650    _2
$a mastocyty $x patologie $7 D008407
650    _2
$a mastocytární sarkom $x genetika $x patologie $x veterinární $7 D012515
650    _2
$a mutace $7 D009154
650    _2
$a protoonkogenní proteiny c-kit $x genetika $7 D019009
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kubickova, Svatava $u Department of Genetics and Reproduction, Central European Institute of Technology, Veterinary Research Institute, Brno, Czech Republic
700    1_
$a Pal, Karol $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Fröhlich, Jan $u Department of Genetics and Reproduction, Central European Institute of Technology, Veterinary Research Institute, Brno, Czech Republic
700    1_
$a Fictum, Petr $u Department of Pathological Morphology and Parasitology, Faculty of Veterinary Medicine, University of Veterinary and Pharmaceutical Sciences Brno, Czech Republic
700    1_
$a Rubes, Jiri $u Department of Genetics and Reproduction, Central European Institute of Technology, Veterinary Research Institute, Brno, Czech Republic
773    0_
$w MED00007703 $t Veterinary and comparative oncology $x 1476-5829 $g Roč. 18, č. 4 (2020), s. 509-518
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31999054 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132937 $b ABA008
999    __
$a ok $b bmc $g 1715196 $s 1146911
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 18 $c 4 $d 509-518 $e 20200207 $i 1476-5829 $m Veterinary and comparative oncology $n Vet Comp Oncol $x MED00007703
GRA    __
$a 16-26655S $p Grantová Agentura České Republiky
GRA    __
$a LM2015091 $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a LQ1601 $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a RO 0519 $p Ministerstvo Zemědělství
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...